Standard
Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls. / Wriedt, Tanja Roehmer; Skaastrup, Kristoffer Nagy; Andersen, Pernille Lindsoe; Simmelsgaard, Line; Jemec, Gregor B. E.; Saunte, Ditte M. L.
I:
APMIS, Bind 131, Nr. 11, 2023, s. 561-563.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Wriedt, TR, Skaastrup, KN, Andersen, PL, Simmelsgaard, L
, Jemec, GBE & Saunte, DML 2023, '
Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls',
APMIS, bind 131, nr. 11, s. 561-563.
https://doi.org/10.1111/apm.13293APA
Wriedt, T. R., Skaastrup, K. N., Andersen, P. L., Simmelsgaard, L.
, Jemec, G. B. E., & Saunte, D. M. L. (2023).
Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls.
APMIS,
131(11), 561-563.
https://doi.org/10.1111/apm.13293Vancouver
Wriedt TR, Skaastrup KN, Andersen PL, Simmelsgaard L
, Jemec GBE, Saunte DML.
Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls.
APMIS. 2023;131(11):561-563.
https://doi.org/10.1111/apm.13293Author
Wriedt, Tanja Roehmer ; Skaastrup, Kristoffer Nagy ; Andersen, Pernille Lindsoe ; Simmelsgaard, Line ; Jemec, Gregor B. E. ; Saunte, Ditte M. L. / Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls. I: APMIS. 2023 ; Bind 131, Nr. 11. s. 561-563.
Bibtex
@article{cd70af8932f64adf8333d8015cad32fb,
title = "Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls",
keywords = "dermatophytes, disinfection, onychomycosis, Tinea",
author = "Wriedt, {Tanja Roehmer} and Skaastrup, {Kristoffer Nagy} and Andersen, {Pernille Lindsoe} and Line Simmelsgaard and Jemec, {Gregor B. E.} and Saunte, {Ditte M. L.}",
note = "Funding Information: TRW has nothing to disclose. KNS has nothing to disclose. PLA has received support from Naestved, Slagelse, and Ringsted Hospitals' Research Fund and from LEO Foundation (grant no.: LF18002). LS have nothing to disclose. GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre and UCB for participation on advisory boards, and grants from Abbvie, Astra‐Zeneca, Inflarx, Janssen‐Cilag, Leo Pharma, Novartis, Regeneron and Sanofi, for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer‐Ingelheim, Galderma and MSD. He has also received unrestricted departmental grants from Abbvie, Leo Pharma and Novartis. DMLS reports personal fees from AbbVie, Janssen, Jamjoom Pharma and Sanofi, grants and personal fees from Abbvie, Leo Pharma and Novartis outside the submitted work.",
year = "2023",
doi = "10.1111/apm.13293",
language = "English",
volume = "131",
pages = "561--563",
journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",
issn = "0903-4641",
publisher = "Wiley Online",
number = "11",
}
RIS
TY - JOUR
T1 - Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls
AU - Wriedt, Tanja Roehmer
AU - Skaastrup, Kristoffer Nagy
AU - Andersen, Pernille Lindsoe
AU - Simmelsgaard, Line
AU - Jemec, Gregor B. E.
AU - Saunte, Ditte M. L.
N1 - Funding Information:
TRW has nothing to disclose. KNS has nothing to disclose. PLA has received support from Naestved, Slagelse, and Ringsted Hospitals' Research Fund and from LEO Foundation (grant no.: LF18002). LS have nothing to disclose. GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre and UCB for participation on advisory boards, and grants from Abbvie, Astra‐Zeneca, Inflarx, Janssen‐Cilag, Leo Pharma, Novartis, Regeneron and Sanofi, for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer‐Ingelheim, Galderma and MSD. He has also received unrestricted departmental grants from Abbvie, Leo Pharma and Novartis. DMLS reports personal fees from AbbVie, Janssen, Jamjoom Pharma and Sanofi, grants and personal fees from Abbvie, Leo Pharma and Novartis outside the submitted work.
PY - 2023
Y1 - 2023
KW - dermatophytes
KW - disinfection
KW - onychomycosis
KW - Tinea
U2 - 10.1111/apm.13293
DO - 10.1111/apm.13293
M3 - Comment/debate
C2 - 36645313
AN - SCOPUS:85146738018
VL - 131
SP - 561
EP - 563
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 11
ER -
